top of page
Chart & Stethoscope

Reach Pharmaceuticals Providing Emerging Therapeutics Globally  

Company

News

January 2023: The TGA approved the importation of KEFORAL CEFALXIN 250 MG/5 ML GRANULES FOR ORAL SUSPENSION under S19A of the Therapeutic Goods Act, 1989 until December 31, 2023.

December 2022: REACH received Orphan Drug Designation for Nelarabine for infusion from the TGA in Australia.

December 2022: REACH received approval for ROMIDEPSIN-REACH powder for injection in Australia.

 

December 2022: The TGA approved the importation of AMOXICILLIN 125MG/5ML ORAL SUSPENSION SUGAR FREE BP (ATHLONE) under S19A of the Therapeutic Goods Act, 1989 until June 30, 2023.

November 2022: The TGA approved the importation of METRONIDAZOLE 200MG/5ML ORAL SUSPENSION (ROSEMONT) under S19A of the Therapeutic Goods Act, 1989 until February 28, 2023.

August, 2022: The TGA approved the importation of OLENA fluoxetine hydrochloride 20 mg dispersible tablet under S19A of the Therapeutic Goods Act, 1989 until November 30, 2022.

August, 2022: The TGA approved the importation of AMOXICILLIN 250MG/5ML ORAL SUSPENSION SUGAR FREE BP (KENT) under S19A of the Therapeutic Goods Act, 1989 until February 28, 2023.

​July, 2022: Reach received Orphan Drug Designation for Carboprost for injection from the Therapeutic Goods Administration.

 

June, 2022: Our online store is now live! Visit the Shop tab to order the available products or click here.

​June, 2022: Reach is pleased to announce the approval of THIOTEPA-REACH 15 mg powder for injection and THIOTEPA-REACH 100 mg powder for injection in Australia.  For more details please contact us on sales@reach-pharma.com. The PI is available from the TGA website, click here 

​June, 2022: Reach is pleased to announce the launch of Cipla Isoprenaline for injection 0.2mg/mL, 25 ampoules and Cipla Isoprenaline for injection 1mg/5mL, 10 ampoules.  For more details please contact us on sales@reach-pharma.com. The PI is available from the TGA website, click here 

 

June, 2022: Reach is pleased to announce the launch of Metabolics Potassium Citrate 1.08g modified release tablets.  For more details please contact us on sales@reach-pharma.com. The CMI is available here

January, 2022: The TGA approved the importation of Xylanaest 1% with Epinephrine 1:200,000 5ml ampoule under S19A of the Therapeutic Goods Act, 1989 until November 30, 2022. 

December, 2021: The TGA approved the importation of Thiotepa for Injection, USP 15 mg AND Thiotepa for injection Injection, USP 100 mg under S19A of the Therapeutic Goods Act, 1989 until September 30, 2022. 

June, 2020: The TGA approved the importation of Isoproterenol Hydrochloride Injection, USP 1 mg/5 mL solution for injection ampoule AND Isoproterenol Hydrochloride Injection, USP 0.2 mg/1 mL solution for injection ampoule under S19A of the Therapeutic Goods Act, 1989 until April 30, 2022.

October, 2020: Icatibant 30mg/3mL is available from Reach for supply to hospitals in Australia. The product was listed on the PBS in October.​​ The PI is available from the TGA website, click here

COMPANY NEWS
EXPERTISE

Source & Supply

We are actively involved in the pharmaceuticals market, to source and supply treatments globally

Market pathways

Over15 years experience in new product launches spanning from regulatory affairs  to customer identification

Consultancy

Business planning, product registration and market insight

Expertise

PRODUCTS

 Products

  • Facebook - White Circle
  • LinkedIn - White Circle
  • Twitter - White Circle
ABOUT US
Screen Shot 2020-04-16 at 4.02.35 pm.png

Reach Pharmaceuticals is an Australian privately-owned pharmaceutical company established in 2018 with a focus on marketing of innovative products that have a first to market advantage. The company also registers and supplies complex generics and other therapeutic goods formulated based on demand from clinicians.

Our pipeline includes thiotepa, potassium citrate, isoprenaline, icatibant, urokinase, carboprost and romidepsin to name a few. We have the capabilities to pursue compassionate supplies of products to fulfil shortages and manage the entire process from product identification to generation of sales.

The company is a leader in the hospital pharmaceuticals space and holds majority market share for all the products launched to date whether registered or supplied under compassionate supplies. We also have an interest in distribution of branded products and will be pursuing launch of new products in the future.

About Us

CONTACT US

Contact Us

Location:

Ground Floor, Corporate One

84 Hotham Street

Preston VIC 3072

Email:

info@reach-pharma.com

sales@reach-pharma.com

For medical enquiries:

medical@reach-pharma.com

Phone:

General & Sales: 0422 429 648

 

Medical enquiries or reporting adverse events: 1800 505 306

Screen Shot 2020-04-16 at 4.02.35 pm.png

Thanks for submitting!

We will be in contact shortly. 

bottom of page